Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer

Clinical and Translational Oncology

Volumn 7, Issue 4, 2005, Pages 150-155

  Bazo, Ignacio Gil ^a   González, Victoria Catalán ^a   Gutiérrez, Álvaro Alonso ^b   Rodríguez, Javier Rodríguez ^a   Fernández, José Antonio Páramo ^a   De La Cámara Gómez, Juan ^a   Lizoain, José Luis Hernández ^a   López, Jesús García Foncillas ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Angiogenesis; Colorectal cancer; VEGF; VWf

Indexed keywords

VASCULOTROPIN A; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; COLORECTAL TUMOR; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 24344436362     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02708752     Document Type: Article

References (29)

1. Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost. 1978; 5: 1-26.
2. Lip GY, Chin BS, Blann AD Cancer and the prothrom-botic state. Lancet Oncol. 2002; 3: 27-34.
3. Páramo J., Campbell W, Cuesta B., Gómez C, Aranda A., Rocha E. Fibrinolytic response in malignancy. Fibrinolysis. 1987; 1: 195-9.
4. Rickles FR, Edwards RL Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood. 1983; 62: 14-31.
5. Sorensen HT, Mellemkjaer L, Steffensen F.H., Olsen JH, Nielsen GL The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998; 338: 1169-73.
6. Gadducci A, Baicchi U, Marrai R., Del Bravo B, Fosella PV, Facchini V. Pretreatment plasma levels of fibrino-peptide - A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecol Oncol. 1994; 53: 352-6.
7. Morganti M, Carpi A, Amo-Takyi B, et al Von Wille-brand's factor mediates the adherence of human tumoral cells to human endothelial cells and ticlopidine interferes with this effect. Biomed Pharmacother. 2000; 54: 431-6.
8. Paczuski R, Bialkowska A, Kotschy M., Burduk D, Betlejewski S. Von Willebrand factor in plasma of patients with advanced stages of larynx cancer. Thromb Haemost. 1999; 95: 197-200.
9. Sweeney JD, Killion KM, Pruet C.F., Spaulding MB Von Willebrand factor in head and neck cancer. Cancer. 1990; 66: 2387-9.
10. Zietek Z, Iwan-Zietek I, Paczulski R., Kotschy M, Wolski Z. Von Willebrand factor antigen in blood plasma of patients with urinary bladder carcinoma. Thromb Res. 1996; 83: 399-402.
11. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al Phase II, randomized trial comparing bevacizumab plus fluo-rouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21: 60-5.
12. Senger DR. Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol. 1996; 149: 1-7
13. Weidner N, Semple JP, Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991; 324: 1-8.
14. Guidi AJ, Schnitt SJ, Fischer L, et al Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer. 1997; 80: 1945-53.
15. Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res. 1997; 3: 2187-90.
16. Zanetta L, Marcus SG, Vasile J, et al Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int J Cancer. 2000; 85: 281-8.
17. Felding-Habermann B., O'Toole TE, Smith JW, et al In-tegrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA. 2001; 98: 1853-8.
18. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet. 1998; 352: 1775-7.
19. Trikha M, Zhou Z, Timar J., et al Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 2002; 62: 2824-33.
20. Pottinger BE, Read RC, Paleolog E.M., Higgins PG, Pearson JD Von Willebrand factor is an acute phase reactant in man. Thromb Res. 1989; 53: 387-94.
21. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg. 2002; 236: 37-42.
22. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997; 90: 3167-72.
23. Wartiovaara U, Salven P, Mikkola H., et al Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998; 80: 171-5.
24. George ML, Eccles SA, Tutton M.G., Abulafi AM, Swift RI Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res. 2000; 6: 3147-52.
25. Werther K, Christensen IJ, Nielsen HJ Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer. 2002; 86: 417-23.
26. Ikeda M, Furukawa H, Imamura H., et al Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor. Gastric Cancer. 2002; 5: 137-41.
27. Fujii T, Tachibana M, Dhar D.K., et al Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice. Anticancer Res. 2003; 23: 2405-11.
28. Lennernas B, Albertsson P, Lennernas H., Norrby K. Chemotherapy and antiangiogenesis-drug-specific, dose-related effects. Acta Oncol. 2003; 42: 294-303.
29. Berglund A, Molin D, Larsson A., Einarsson R, Glimelius B. Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol. 2002; 13: 1430-7